Synaptogenix implementing reverse stock split to maintain Nasdaq listing

Synaptogenix intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 25 pre-split shares. SNPX common stock will continue to be traded on Nasdaq under the symbol SNPX and will begin trading on a split-adjusted basis when the market opens on Friday, April 5. The new CUSIP number for SNPX common stock following the reverse stock split will be 87167T 300. The reverse split is intended to increase the per-share trading price of the company’s common stock to enable the company to regain compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market. The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the company’s equity. The reverse stock split will reduce the number of shares of SNPX common stock outstanding from 27,133,349 shares, the number of shares outstanding on April 2, to approximately 1,085,333 shares, subject to adjustment for fractional shares.